Last checked at Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
6 Feb 20 14:17
- Home
- Share Prices
- NEX Exchange Share Prices
- Share Chat
- FX
- News
- Blogs
- RNS
- Media
- Trading
- Finance Tools
- Members
Latest Share Chat
Faron Pharma Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat53
FARN Share
Trades127
FARN
Live RNS1
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Information
Share Price Information for Faron Pharma (FARN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
365.00
Bid:
355.00
Ask:
375.00
Change:
45.00
(14.06%)
Spread:
20.00 (5.63%)
Open:
340.00
High:
385.00
Low:
340.00
Yest. Close:
320.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.6 Feb 20 14:17Faron Pharma To Test Clevegen In Patients With Ovarian Cancer
Faron Pharma To Test Clevegen In Patients With Ovarian Cancer
27 Jan 20 11:22Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug
Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug
13 Jan 20 11:54Faron Pharma requests arbitration over Traumakine manufacturing deal
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.
30 Dec 19 15:39Faron Pharma Files For Arbitration Amid Traumakine Deal Termination
Faron Pharma Files For Arbitration Amid Traumakine Deal Termination
30 Dec 19 10:56Faron Pharmaceuticals upbeat on new data from 'MATINS' study
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.
11 Dec 19 13:42Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
11 Dec 19 10:45Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
29 Nov 19 10:23Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
28 Nov 19 11:56Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing
Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing
21 Nov 19 12:56UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
8 Nov 19 10:30Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
7 Nov 19 17:59LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
1 Nov 19 16:58Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge
Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge
1 Nov 19 15:32Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.
9 Oct 19 14:05